LIPELLA PHARMACEUTICALS INC (LIPO) Stock Price & Overview
NASDAQ:LIPO • US53630L2097
The current stock price of LIPO is 2.36 USD. Today LIPO is down by -12.75%. In the past month the price decreased by -23.38%. In the past year, price decreased by -48.25%.
LIPO Key Statistics
- Market Cap
- 10.549M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.10
- Dividend Yield
- N/A
LIPO Stock Performance
LIPO Stock Chart
LIPO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LIPO. When comparing the yearly performance of all stocks, LIPO is a bad performer in the overall market: 90.5% of all stocks are doing better.
LIPO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIPO. While LIPO has a great health rating, there are worries on its profitability.
LIPO Earnings
LIPO Forecast & Estimates
7 analysts have analysed LIPO and the average price target is 10.2 USD. This implies a price increase of 332.2% is expected in the next year compared to the current price of 2.36.
For the next year, analysts expect an EPS growth of 33.76% and a revenue growth -100% for LIPO
LIPO Groups
Sector & Classification
LIPO Financial Highlights
Over the last trailing twelve months LIPO reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS decreased by -56.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.66% | ||
| ROE | -125.78% | ||
| Debt/Equity | 0 |
LIPO Ownership
LIPO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LIPO
Company Profile
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.
Company Info
IPO: 2022-12-20
LIPELLA PHARMACEUTICALS INC
400 N Lexington St Ste LL103
Pittsburgh PENNSYLVANIA US
Employees: 5
Phone: 14129010315
LIPELLA PHARMACEUTICALS INC / LIPO FAQ
What does LIPO do?
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.
Can you provide the latest stock price for LIPELLA PHARMACEUTICALS INC?
The current stock price of LIPO is 2.36 USD. The price decreased by -12.75% in the last trading session.
What is the dividend status of LIPELLA PHARMACEUTICALS INC?
LIPO does not pay a dividend.
How is the ChartMill rating for LIPELLA PHARMACEUTICALS INC?
LIPO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is LIPELLA PHARMACEUTICALS INC (LIPO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LIPO.
Can you provide the market cap for LIPELLA PHARMACEUTICALS INC?
LIPELLA PHARMACEUTICALS INC (LIPO) has a market capitalization of 10.55M USD. This makes LIPO a Nano Cap stock.